JMBI-001 / Anticancer Biosci - LARVOL DELTA

Anticancer Bioscience Announces Preclinical Data of Lead Compounds Against Novel Myc Synthetic Lethal Target in Cancer (Businesswire) - “Anticancer Bioscience…announced today progress in its MYC-synthetic lethal (MYC-SL) programme. The Company has identified three classes of novel small molecule compounds that demonstrate robust anti-cancer activity in preclinical studies, acting through interfering with mitosis and blocking cytokinesis. ACB is progressing through optimization and final candidate selection with the goal of progressing at least one of these MYC-SL compounds into clinical trials by 2022…In animal models, data consistent with the in vitro studies has confirmed that the MYC-SL compounds act through interfering mitosis and blocking cytokinesis.”

Preclinical • Synthetic lethality • Trial status • Oncology